Skip to main content

Lemtrada FDA Approval History

FDA Approved: Yes (First approved November 14, 2014)
Brand name: Lemtrada
Generic name: alemtuzumab
Dosage form: Injection
Company: Genzyme Corporation
Treatment for: Multiple Sclerosis

Lemtrada (alemtuzumab) is a CD52-directed cytolytic monoclonal antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS).

Development timeline for Lemtrada

DateArticle
Nov 14, 2014Approval FDA Approves Lemtrada (alemtuzumab) for Relapsing Forms of Multiple Sclerosis
Dec 30, 2013Genzyme Receives Complete Response Letter from FDA on Lemtrada (alemtuzumab) Application
Jan 28, 2013Genzyme's Lemtrada (alemtuzumab) Application for MS Accepted for Review by the FDA
Aug 27, 2012Genzyme Provides Update on U.S. Lemtrada Filing
Jun 12, 2012Genzyme Submits Applications to FDA and EMA for Approval of Lemtrada (alemtuzumab) for Multiple Sclerosis

See also

Lemtrada (alemtuzumab) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer